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INTRODUCTION
Macrophage activation syndrome (MAS) is a clinical entity
characterized by serious liver diseases, hematologic abnormali-
ties, coagulopathy resembling disseminated intravascular
coagulation, and neurologic involvement. MAS is known to
be a severe and potentially life-threatening complication of
rheumatic disorder, especially systemic juvenile rheumatoid
arthritis (S-JRA) (1).
MAS is a rarely-occurring disorder, and only sporadic case
reports or several studies with relatively small number of
patients are available in the literature (2-4). In Korea, only
two cases of MAS associated with S-JRA have been reported
(5, 6). Here we describe a 13-month-old boy, in whom MAS
developed as a complication of S-JRA. This is the third case
of MAS in Koreans, and the first one, in which hemophago-
cytic macrophages were proven in bone marrow (BM).
CASE REPORT
A 13-month-old boy, who had suffered from fever, gener-
alized rash, and multiple joints swelling for four months,
visited pediatric rheumatology clinic. At admission, fever,
which had shown an intermittent high pattern, nearly sub-
sided, but salmon pink-colored rheumatoid rash was diffusely
present on his abdomen. His hands, lower legs and feet were
bilaterally swelled with the involvement of metacarpal and
proximal interphalangeal joints of second fingers, knee joints,
and fifth toes (Fig. 1). Physical examination revealed cervical
lymphadenopathy and hepatosplenomegaly. Under the diag-
nosis of S-JRA, he had been treated with aspirin (100 mg/kg
for nine days) and ibuprofen at local hospital until one week
before admission.
Laboratory results of rheumatoid factor, anti-streptolysin
O, lupus anticoagulant, and antinuclear antibody were all
negative. Complement and immunoglobulin data were: C3,
199 mg/dL; C4, 33.5 mg/dL; IgG, 766 mg/dL; IgA, 112
mg/dL; and IgM, 81.5 mg/dL. There was no evidence of viral
infection or hepatitis. Other laboratory findings at admission
are presented in Table 1.
Bone marrow (BM) examination, which was performed as
a further work-up of hematologic abnormalities showed nor-
mocellular marrow with a cellularity of 90%. Granulocytic
and megakaryocytic lineages were normal in maturation, but
erythroid lineage was hypoplastic. Benign-looking macro-
phages were remarkably increased, and some of them showed
hemophagocytic features. Their presence was confirmed with
CD68 immunostain (Fig. 2).
He was diagnosed as having MAS. Immunosuppressive
therapy with methylprednisolone (2 mg/kg/day for three days,
and switched to oral prednisolone) and cyclosporin (2.5 mg/
kg/day, under continuous medication) was started from the
third and the ninth hospital days, respectively. Clinical and
laboratory findings improved with decreased hepatomegaly
and joints swelling at the time of discharge (Fig. 3-5). He
has remained stable without relapse of MAS during the fol-
low-up period of six months.
Mina Hur, Young Chul Kim,
Kyu Man Lee, Kwang Nam Kim*
Departments of Laboratory Medicine and Pediatrics*, 
Hallym University College of Medicine, Seoul, Korea
Address for correspondence
Kwang Nam Kim, M.D.
Department of Pediatrics, Hallym University College of
Medicine, Hangang Sacred Heart Hospital, 94-200
Youngdeungpo-dong, Youngdeungpo-gu, Seoul
150-719, Korea
Tel : +82.2-2639-5200, Fax : +82.2-2637-1006
E-mail : rheumatol@hanmail.net
695
J Korean Med Sci 2005; 20: 695-8
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Macrophage Activation Syndrome in a Child with Systemic Juvenile
Rheumatoid Arthritis
Macrophage activation syndrome (MAS) is a rare and potentially fatal complication
of rheumatic disorders in children. We describe a 13-month-old boy in whom MAS
developed as a complication of systemic juvenile rheumatoid arthritis (S-JRA). He
suffered from fever and generalized rash followed by multiple joints swelling for four
months before admission. Physical examination revealed cervical lymphadenopa-
thy and hepatosplenomegaly. Laboratory findings were: abnormal liver enzymes,
increased triglyceride and ferritin levels, coagulopathies resembling disseminated
intravascular coagulation, anemia and thrombocytopenia. Hyperplasia of hemophago-
cytic macrophages was remarkable in his bone marrow. Methylprednisolone and
cyclosporin therapy resulted in clinical and laboratory improvements. This is the
third case of MAS associated with S-JRA in Koreans, and the first one, in which
hemophagocytic macrophages were proven in bone marrow.
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DISCUSSION
In 1985, Hadchouel et al. described seven patients who
showed unique clinical features with hematologic, neurologic,
and hepatic abnormalities in association with S-JRA (7, 8).
Since they suggested the term MAS in 1993, MAS has been
commonly used to identify the hemophagocytic syndrome
that may develop in children with chronic rheumatic diseases,
particularly S-JRA (9).
MAS is a potentially fulminant disorder, and occurs dur-
ing the clinical course of underlying S-JRA characterized by
repetitive disease flares. It is thus very important to differenti-
ate the onset of MAS from a flare of the disease, as they have
different treatments and prognoses. Clinically, the patterns
of fever and skin rash are somewhat different, although both
of the diseases share lymphadenopathy and hepatosplenome-
galy (1). From the aspect of laboratory findings, decreases of
blood cells, erythrocyte sedimentation rate, and fibrinogen
present striking contrasts to S-JRA. Hypertriglyceridemia,
elevated liver enzymes, and abnormal coagulation profile are
consistently found. Hyperferritinemia greater than 10,000
ng/mL is known to be also remarkable heralding MAS devel-
opment, thus making early and aggressive immunosuppres-
sion possible (4, 10, 11).
The patient described here showed typical clinical and lab-
oratory features of MAS, which changed dramatically after
the initiation of immunosuppressive treatment (Fig. 3-5).
To our knowledge, two cases of MAS were previously reported
in Koreans (5, 6). Three cases including our case are summa-
rized in Table 1. Although they were all pediatric patients
suffering from S-JRA, MAS can also develop in other rheumatic
disorders as well as in adults (2, 4).
The pathognomonic feature of MAS is numerous well dif-
Kim et al. 
(1988)*
Park et al.
(1998)
Present case
Sex/age Male/9 yr Female/13 yr Male/13 months
Underlying S-JRA S-JRA S-JRA
disease
Disease duration 7 yr 8 yr 3 months
Hemoglobin (g/dL) NA 7.6 6.9
White blood cell  NA 4.5 6.1
(×10
9/L)
Platelet (×10
9/L) 60 157→51 55
ESR (mm/hr) NA 36 17
Bleeding time (min) >10 NA NA
Prothrombin time (sec) 18 20.5 21.2
aPTT (sec) 77.6 66 37.4
Fibrinogen (mg/dL) NA 40 31.2
FDP ( g/mL) 80 20 >20
AST (IU/L) NA 244 2,090
ALT (IU/L) NA 97 560
LDH (IU/L) NA 6,345 7,880
ALP (IU/L) NA NA 2,751
GGT (IU/L) NA NA 227
Triglyceride (mg/dL) NA NA 326
Ferritin (ng/mL) NA NA 28,589
Treatment FFP, Methylpredni- Methylpredniso-
Antibiotics solone, IVIG lone, Cyclosporin
Possible triggers Pneumonia Sulfasalazine Aspirin
Salicylates Naproxen Ibuprofen
Clinical course Recovered Expired Recovered
Table 1. Cases of macrophage activation syndrome in Koreans
*In this case, detailed laboratory data on liver function and complete
blood cell count except platelet count was unavailable at the onset of
coagulopathy. ESR, erythrocyte sedimentation rate; aPTT, activated par-
tial thromboplastin time; FDP, fibrin degradation product; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydro-
genase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase;
S-JRA, systemic juvenile rheumatoid arthritis; NA, not available; FFP, fresh
frozen plasma; IVIG, intravenous immunoglobulin.
Fig. 1. Swelling of both lower legs and feet.
Fig. 2. Bone marrow biopsy section shows increased numbers of
diffusely distributed and minimally clustered macrophages (CD68
immunostain, ×200).Macrophage Activation Syndrome in Systemic JRA 697
ferentiated macrophages actively phagocytosing hematopoi-
etic elements in BM. Hemophagocytic macrophages can also
be found in spleen or lymph nodes. BM examination, how-
ever, may reveal false negative result related to a sampling
error or the timing of aspiration during disease course (1, 2,
4). Accordingly, morphologic confirmation is not a prereq-
uisite for the diagnosis of MAS. BM study was not performed
in both of the previous Korean cases. However, coagulopathies
resembling disseminated intravascular coagulation as well as
other laboratory or clinical findings support their diagnoses
of MAS.
Although the mechanism of MAS is still poorly under-
stood, it is known that cytokine storm plays a major role. T
cell or natural killer cell dysfunction may lead to uncontrolled
macrophage activation, and increased levels of many cytokines,
representatively tumor necrosis factor-alpha or interferon-
gamma, released by macrophages or T cells initiate systemic
hemophagocytosis (9, 11-13). At molecular level, dysfunc-
tional perforin was recently suggested as a possible cause of
this condition (11, 14).
Triggering episodes like infections or medications may
precede the onset of MAS, and they have been reported in at
least 58% to 88.9% of patients (1, 2). The possibility of trig-
gers also existed in all of the three Korean cases (Table 1). In
the patient by Kim et al., there was a history of infection and
salicylates medication four to six weeks prior to the onset of
coagulopathy (5). The other two patients by Park et al. and
by us recently received anti-inflammatory drugs (6).
With regard to nomenclature, the term reactive hemophago-
cytic lymphohistiocytosis is interchangeably used with MAS
(1, 15). Although MAS is widely used in the field of rheuma-
tology, this is relatively unfamiliar to specialists in other fields
such as infectious disease or hematology. MAS is even not
included in the recently proposed classification of histiocytic
disorders (16, 17). Some researchers insisted that MAS should
belong to the category of secondary hemophagocytic syndrome
likewise infection or malignancy-associated ones, and the
term rheumatic disease-associated hemophagocytic syndrome
is preferable to MAS (18-20). We agree with their opinion
in that such unifying criteria would be beneficial for inves-
tigating etiologic relationships or developing treatment strate-
gies among the related disorders.
In summary, we report a case of MAS in a 13-month-old
boy suffering from S-JRA. His clinical and laboratory fea-
tures were typical of MAS, and his clinical course improved
after immunosuppressive therapy with methylprednisolone
and cyclosporin. This is the third case of MAS in Koreans,
and the first one, in which hemophagocytic macrophages
were proven in BM.
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Fig. 3. Laboratory findings of liver enzymes during hospital days.
AST, aspartate aminotransferase; ALT, alanine aminotransferase;
ALP, alkaline phosphatase; GGT, gamma glutamyl transferase;
LDH, lactate dehydrogenase; HD, hospital day.
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Fig. 4. Laboratory findings of PT, aPTT, and fibrinogen during hos-
pital days. PT, prothrombin time; aPTT, activted partial thrombo-
plastin time; HD, hospital day.
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Fig. 5. Laboratory findings of complete blood cell counts during
hospital days. At the third hospital day, red blood cell was trans-
fused. Hb, hemoglobin; WBC, white blood cell; PLT, platelet; HD,
hospital day.
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